US5095026A
(en)
*
|
1983-02-04 |
1992-03-10 |
University Of Iowa Research Foundation |
Prodrugs of carbonic anhydrase inhibitors
|
US5200180A
(en)
*
|
1987-06-26 |
1993-04-06 |
Christian Bannert |
Pharmaceutical composition for the treatment of the human eye
|
FR2618333B1
(fr)
*
|
1987-07-20 |
1990-07-13 |
Merck Sharp & Dohme |
Composition pharmaceutique et/ou cosmetique a usage topique contenant de la gomme rhamsam
|
US5843156A
(en)
|
1988-08-24 |
1998-12-01 |
Endoluminal Therapeutics, Inc. |
Local polymeric gel cellular therapy
|
US4911926A
(en)
*
|
1988-11-16 |
1990-03-27 |
Mediventures Inc. |
Method and composition for reducing postsurgical adhesions
|
US6436425B1
(en)
|
1988-11-16 |
2002-08-20 |
Mdv Technologies, Inc. |
Method and non-gelling composition for inhibiting post-surgical adhesions
|
US5034406A
(en)
*
|
1989-09-26 |
1991-07-23 |
Allergan, Inc. |
Method for reducing or maintaining intraocular pressure
|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
FR2653018A1
(fr)
|
1989-10-17 |
1991-04-19 |
Merck Sharp & Dohme |
Composition ophtalmique non solide a base de microparticules de polymere contenant au moins un principe actif en suspension dans un milieu dispersant et procede de preparation de ladite composition.
|
FR2653021A1
(fr)
*
|
1989-10-17 |
1991-04-19 |
Merck Sharp & Dohme |
Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
|
US5141928B1
(en)
*
|
1989-12-20 |
1995-11-14 |
Brujo Inc |
Ophthalmic medication
|
US5496471A
(en)
*
|
1990-01-08 |
1996-03-05 |
Ciba-Geigy Corporation |
Apparatus for removing components from solutions
|
FR2657018A1
(fr)
*
|
1990-01-12 |
1991-07-19 |
Merck Sharp & Dohme |
Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
|
US5593683A
(en)
*
|
1990-05-01 |
1997-01-14 |
Mdv Technologies, Inc. |
Method of making thermoreversible polyoxyalkylene gels
|
US5298260A
(en)
*
|
1990-05-01 |
1994-03-29 |
Mediventures, Inc. |
Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality
|
US5252318A
(en)
*
|
1990-06-15 |
1993-10-12 |
Allergan, Inc. |
Reversible gelation compositions and methods of use
|
CA2044878C
(en)
*
|
1990-08-07 |
2000-12-26 |
Tacey X. Viegas |
Thermally reversible and irreversible gels
|
US5346703A
(en)
|
1990-08-07 |
1994-09-13 |
Mediventures, Inc. |
Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
|
FR2665635A1
(fr)
*
|
1990-08-10 |
1992-02-14 |
Merck Sharp & Dohme |
Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
|
US5847023A
(en)
*
|
1990-10-26 |
1998-12-08 |
Mdv Technologies, Inc. |
Thermal irreversible gel corneal contact lens formed in situ
|
DE69212850T2
(de)
*
|
1991-01-15 |
1997-03-06 |
Alcon Lab Inc |
Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
|
US5212162A
(en)
*
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
SG84487A1
(en)
|
1991-04-17 |
2001-11-20 |
Merck & Co Inc |
Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
|
ZA927277B
(en)
*
|
1991-10-02 |
1993-05-19 |
Boston Ocular Res |
Dry eye treatment process and solution.
|
US5318780A
(en)
*
|
1991-10-30 |
1994-06-07 |
Mediventures Inc. |
Medical uses of in situ formed gels
|
ATE189772T1
(de)
*
|
1993-04-16 |
2000-03-15 |
Wakamoto Pharma Co Ltd |
Unter wärmeeinwirkung reversibel gelierende medizinische zusammensetzung auf wasserbasis
|
SE9301877D0
(sv)
*
|
1993-06-02 |
1993-06-02 |
Kabi Pharmacia Ab |
In situ gel for therapeutic use
|
US5545617A
(en)
*
|
1993-11-12 |
1996-08-13 |
The Schepens Eye Research Institute, Inc. |
Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
|
AU684950B2
(en)
*
|
1994-05-06 |
1998-01-08 |
Alcon Laboratories, Inc. |
Use of vitamin E tocopheryl derivatives in ophthalmic compositions
|
IL114193A
(en)
*
|
1994-06-20 |
2000-02-29 |
Teva Pharma |
Ophthalmic pharmaceutical compositions based on sodium alginate
|
US5585398A
(en)
*
|
1994-07-15 |
1996-12-17 |
Ernst; Amy A. |
Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
|
US6316443B1
(en)
|
1994-08-04 |
2001-11-13 |
Merck & Co., Inc. |
Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
|
US5827835A
(en)
*
|
1994-08-30 |
1998-10-27 |
Alcon Laboratories, Inc. |
Thermally-gelling emulsions
|
DK0725628T3
(da)
*
|
1994-08-30 |
2001-12-27 |
Alcon Lab Inc |
Termisk geldannende lægemiddelindgivelsesvehikler indeholdende celluloseethere
|
US5516808A
(en)
*
|
1994-10-27 |
1996-05-14 |
Sawaya; Assad S. |
Topical cellulose pharmaceutical formulation
|
US5603929A
(en)
*
|
1994-11-16 |
1997-02-18 |
Alcon Laboratories, Inc. |
Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
|
US6165490A
(en)
*
|
1996-04-05 |
2000-12-26 |
Staar Surgical Ag |
Biological material, method of preparing such materials, uses thereof and products made therefrom
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
US5843470A
(en)
*
|
1995-10-06 |
1998-12-01 |
Mdv Technologies, Inc. |
Method and composition for inhibiting post-surgical adhesions
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
WO1997018812A1
(en)
*
|
1995-11-17 |
1997-05-29 |
Alcon Laboratories, Inc. |
Combination therapy for treating glaucoma
|
US5866120A
(en)
|
1995-11-22 |
1999-02-02 |
Advanced Corneal Systems, Inc. |
Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
|
US6610292B2
(en)
*
|
1995-11-22 |
2003-08-26 |
Ista Pharmaceuticals, Inc. |
Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
|
US5641532A
(en)
*
|
1995-12-15 |
1997-06-24 |
The Procter & Gamble Company |
Beverages having stable flavor/cloud emulsions in the presence of polyphosphate-containing preservative systems by including gellan gum
|
EP0913159B1
(de)
|
1996-02-13 |
2002-09-25 |
Dainippon Pharmaceutical Co., Ltd. |
Arzneistoffverabreichungssystem unter verwendung von galactoxyloglucan
|
FR2754712B1
(fr)
|
1996-10-17 |
1999-09-03 |
Merck Sharp Dohme Chibret Lab |
Compositions ophtalmiques
|
US5888493A
(en)
*
|
1996-12-05 |
1999-03-30 |
Sawaya; Assad S. |
Ophthalmic aqueous gel formulation and related methods
|
AU6876498A
(en)
*
|
1997-04-03 |
1998-10-22 |
Point Biomedical Corporation |
Intravesical drug delivery system
|
GB9707934D0
(en)
*
|
1997-04-18 |
1997-06-04 |
Danbiosyst Uk |
Improved delivery of drugs to mucosal surfaces
|
ATE250923T1
(de)
|
1997-07-29 |
2003-10-15 |
Alcon Lab Inc |
Galaktomannanpolymere und borat enthaltende augenarzneimittel
|
DK0970175T3
(da)
|
1997-07-29 |
2002-11-04 |
Alcon Lab Inc |
Konditioneringsopløsninger til pleje af hårde kontaktlinser
|
EP0999854B1
(de)
|
1997-07-29 |
2003-10-01 |
Alcon Manufacturing Ltd. |
Galaktomannanpolymere und borat enthaltende viskoelastische systeme mit regelbarer viskosität
|
US20040063678A1
(en)
*
|
1997-10-06 |
2004-04-01 |
Bausch & Lomb Incorporated |
Dexamethasone Gel
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
US6174524B1
(en)
|
1999-03-26 |
2001-01-16 |
Alcon Laboratories, Inc. |
Gelling ophthalmic compositions containing xanthan gum
|
US6312666B1
(en)
*
|
1998-11-12 |
2001-11-06 |
3M Innovative Properties Company |
Methods of whitening teeth
|
US6312667B1
(en)
*
|
1998-11-12 |
2001-11-06 |
3M Innovative Properties Company |
Methods of etching hard tissue in the oral environment
|
US6669927B2
(en)
|
1998-11-12 |
2003-12-30 |
3M Innovative Properties Company |
Dental compositions
|
IL143687A0
(en)
*
|
1998-12-11 |
2002-04-21 |
Khamar Bakulesh Mafatlal |
The process for manufacturing formulation of topical beta blockers with improved efficacy
|
US20030032634A1
(en)
*
|
2001-06-01 |
2003-02-13 |
Piganelli Jon D. |
Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
|
NZ513164A
(en)
*
|
1999-01-25 |
2006-03-31 |
Nat Jewish Med & Res Center |
Substituted porphyrins
|
MXPA02004349A
(es)
|
1999-11-01 |
2003-09-22 |
Alcon Inc |
Composiciones farmaceuticas que contienen un farmaco antibiotico de fluoroquinolona y goma de xantano.
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
PT1305033E
(pt)
|
2000-07-28 |
2005-01-31 |
Alcon Inc |
Composicoes farmaceuticas que contem tobramicina e goma de xantano
|
US20030219461A1
(en)
*
|
2000-09-12 |
2003-11-27 |
Britten Nancy J. |
Parenteral combination therapy for infective conditions
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
JP2002154989A
(ja)
*
|
2000-11-14 |
2002-05-28 |
Lion Corp |
眼科用組成物、及び生体粘膜への薬物の滞留性向上組成物
|
US20090258955A1
(en)
*
|
2000-12-20 |
2009-10-15 |
Alcon, Inc. |
Intraocular irrigating solution having improved flow characteristics
|
AU2002230504A1
(en)
*
|
2000-12-20 |
2002-07-01 |
Alcon Universal Ltd. |
Ophthalmic irrigating solution adapted for use in lasik surgery
|
US7084130B2
(en)
*
|
2001-12-11 |
2006-08-01 |
Alcon, Inc. |
Intraocular irrigating solution having improved flow characteristics
|
AU2002232437A1
(en)
*
|
2000-12-20 |
2002-07-01 |
Alcon Universal Ltd. |
Ophthalmic lubricating solution adapted for use in lasik surgery
|
CA2431367C
(en)
*
|
2000-12-20 |
2010-02-09 |
Alcon, Inc. |
Solution for removing cataracts via liquefracture
|
CA2431368C
(en)
*
|
2000-12-20 |
2006-08-08 |
Alcon, Inc. |
Intraocular irrigating solution having improved flow characteristics
|
US20040121947A1
(en)
*
|
2000-12-28 |
2004-06-24 |
Oklahoma Medical Research Foundation |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
US20020172712A1
(en)
*
|
2001-03-19 |
2002-11-21 |
Alan Drizen |
Antiemetic, anti-motion sustained release drug delivery system
|
US20030013753A1
(en)
*
|
2001-06-05 |
2003-01-16 |
Ronald Aung-Din |
Transdermal migraine therapy
|
US8329734B2
(en)
|
2009-07-27 |
2012-12-11 |
Afgin Pharma Llc |
Topical therapy for migraine
|
US20040266725A1
(en)
|
2001-08-10 |
2004-12-30 |
Toray Industries., Inc. |
Polysaccharide-containing compositions and use thereof
|
US20080199524A1
(en)
*
|
2001-08-10 |
2008-08-21 |
Toray Industries, Inc. |
Eyedrops containing particulate agar
|
US20030220376A1
(en)
*
|
2001-08-10 |
2003-11-27 |
Pharmacia Corporation |
Methods for treating carbonic anhydrase mediated disorders
|
CA2464736A1
(en)
*
|
2001-10-23 |
2003-05-15 |
Oklahoma Medical Research Foundation |
Beta-secretase inhibitors and methods of use
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
US6620405B2
(en)
|
2001-11-01 |
2003-09-16 |
3M Innovative Properties Company |
Delivery of hydrogel compositions as a fine mist
|
CA2477044A1
(en)
*
|
2002-02-22 |
2003-09-04 |
Pharmacia Corporation |
Ophthalmic formulation with gum system
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
US7642258B2
(en)
*
|
2002-04-19 |
2010-01-05 |
Allergan, Inc. |
Combination of brimonidine and timolol for topical ophthalmic use
|
US7030149B2
(en)
|
2002-04-19 |
2006-04-18 |
Allergan, Inc. |
Combination of brimonidine timolol for topical ophthalmic use
|
CA2484797A1
(en)
*
|
2002-05-06 |
2003-11-13 |
Washington University |
Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
|
US20080153894A1
(en)
*
|
2002-12-19 |
2008-06-26 |
Pharmacia Corporation |
Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
|
US20060166879A1
(en)
*
|
2002-12-20 |
2006-07-27 |
Chakshu Research Inc |
Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
|
US20060177430A1
(en)
*
|
2002-12-20 |
2006-08-10 |
Chakshu Research Inc |
Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
|
US20060172972A1
(en)
*
|
2002-12-20 |
2006-08-03 |
Chakshu Research Inc |
Formulation and method for administration of ophthalmologically active agents
|
JP5583310B2
(ja)
*
|
2002-12-20 |
2014-09-03 |
チャクシュ・リサーチ・インコーポレーテッド |
眼球の症状の予防及び治療のための眼科用製剤
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
US20040191332A1
(en)
*
|
2003-03-27 |
2004-09-30 |
Allergan, Inc. |
Preserved ophthalmic compositions
|
CA2529528A1
(en)
*
|
2003-06-20 |
2004-12-29 |
Ronald Aung-Din |
Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
|
EP1683528A4
(de)
*
|
2003-11-10 |
2011-07-27 |
Toray Industries |
Polysaccharid-haltige zusammenstzung und ophthalmische lösung zur stabilisierung des tränenfilms
|
US20050129770A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Alcon, Inc. |
Ophthalmic compositions containing a PVA/borate gelling system
|
CA2545947A1
(en)
*
|
2003-12-11 |
2005-07-07 |
Alcon, Inc. |
Ophthalmic compositions containing a polysaccharide/borate gelling system
|
JP4771044B2
(ja)
*
|
2004-09-15 |
2011-09-14 |
大正製薬株式会社 |
粘膜適用液剤
|
EP1799660A2
(de)
*
|
2004-09-17 |
2007-06-27 |
Comentis, Inc. |
Aminohaltige verbindungen zur inhibition der aktivität von memapsin-2-beta-sekretase und verfahren zu ihrer verwendung
|
EP1797052A1
(de)
*
|
2004-09-17 |
2007-06-20 |
Comentis, Inc. |
Bizyklische verbindungen zur verhinderung der aktivität von beta-sekretase und verwendungsverfahren dafür
|
WO2006039252A2
(en)
*
|
2004-10-01 |
2006-04-13 |
Merck & Co., Inc. |
Compositions and methods for treating ophthalmic diseases
|
JP2008520744A
(ja)
|
2004-11-19 |
2008-06-19 |
ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア |
抗炎症性ピラゾロピリミジン
|
US20070059274A1
(en)
*
|
2004-12-01 |
2007-03-15 |
Bahram Asgharian |
Ophthalmic compositions containing a PVA/borate gelling system
|
US7485619B2
(en)
*
|
2005-01-31 |
2009-02-03 |
Yeon Sook KIM |
Antimicrobial agent
|
JP2008535863A
(ja)
*
|
2005-04-08 |
2008-09-04 |
コメンティス,インコーポレーテッド |
β−セクレターゼ活性を阻害する化合物およびその使用方法
|
CN101262887A
(zh)
*
|
2005-07-15 |
2008-09-10 |
视可舒研究公司 |
糖尿病的眼科并发症的预防和治疗
|
US7534795B2
(en)
*
|
2005-10-25 |
2009-05-19 |
Allergan, Inc. |
Compounds and their use related to compositions for treating disease
|
JP2009514969A
(ja)
|
2005-11-09 |
2009-04-09 |
コンビナトアールエックス インコーポレーティッド |
医学的状態を治療するための方法、組成物、およびキット
|
EP1978926A2
(de)
*
|
2005-12-19 |
2008-10-15 |
Comentis, Inc. |
Topische mecamylamin-formulierungen zur okularen verabreichung und ihre verwendungszwecke
|
TW200808375A
(en)
*
|
2006-05-12 |
2008-02-16 |
Otsuka Pharma Co Ltd |
Hydrogel suspension and manufacturing process thereof
|
KR100802534B1
(ko)
|
2006-06-13 |
2008-02-14 |
주식회사태준제약 |
저자극성 점안제 조성물 및 이의 제조 방법
|
WO2008005457A2
(en)
|
2006-06-30 |
2008-01-10 |
Sunesis Pharmaceuticals |
Pyridinonyl pdk1 inhibitors
|
US8968786B2
(en)
|
2007-06-22 |
2015-03-03 |
Board Of Regents, The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
CA2697166A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Comentis, Inc. |
Isophthalamide derivatives inhibiting betasecretase activity
|
KR20100059919A
(ko)
*
|
2007-09-24 |
2010-06-04 |
코멘티스, 인코포레이티드 |
치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물
|
KR20100133980A
(ko)
*
|
2008-03-07 |
2010-12-22 |
썬 파마 어드밴스트 리서치 컴패니 리미티드 |
안약 조성물
|
ES2464728T3
(es)
|
2008-05-23 |
2014-06-03 |
National Jewish Health |
Compuestos para su uso en el tratamiento de lesiones asociadas con la exposición a una especie química alquilante
|
WO2010005507A1
(en)
|
2008-06-30 |
2010-01-14 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
US8618096B2
(en)
*
|
2008-07-21 |
2013-12-31 |
The Regents Of The University Of California |
Prodrug compositions and methods for using the same in treating cancer and malaria
|
CN104230901A
(zh)
|
2008-09-15 |
2014-12-24 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
JP2010132587A
(ja)
*
|
2008-12-03 |
2010-06-17 |
Teika Seiyaku Kk |
眼科用剤
|
US8580947B2
(en)
|
2009-02-05 |
2013-11-12 |
Gene Signal International Sa |
Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
|
US8470997B2
(en)
*
|
2009-02-05 |
2013-06-25 |
Gene Signal International Sa |
Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
|
MX2011008647A
(es)
*
|
2009-02-20 |
2011-10-28 |
Micro Labs Ltd |
Producto de prostaglandina de almacenamiento estable.
|
EP2467142B1
(de)
|
2009-08-17 |
2016-09-21 |
Memorial Sloan-Kettering Cancer Center |
2-(Pyrimidin-5-yl)-Thiopyrimidine Derivate als Hsp70 and Hsc70 Modulatoren zur Behandlung von proliferativen Erkrankungen
|
NZ598985A
(en)
|
2009-09-04 |
2013-07-26 |
Biogen Idec Inc |
Bruton's tyrosine kinase inhibitors
|
US9029359B2
(en)
|
2009-09-04 |
2015-05-12 |
Biogen Idec Ma, Inc. |
Heteroaryl Btk inhibitors
|
US8679511B2
(en)
*
|
2009-10-01 |
2014-03-25 |
Duquesne University of the Holy Spririt |
In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
|
WO2011044157A1
(en)
|
2009-10-06 |
2011-04-14 |
Biogen Idec Ma Inc. |
Heterocyclic compounds useful as pdk1 inhibitors
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
AU2010315561B2
(en)
|
2009-10-26 |
2016-10-20 |
Sephoris Pharmaceuticals, Llc |
Treatment of sunburn using analgesics and antihistamines
|
US20130035325A1
(en)
|
2009-11-16 |
2013-02-07 |
The Regents Of The University Of California |
Kinase inhibitors
|
RS54158B1
(en)
|
2009-12-10 |
2015-12-31 |
The Regents Of The University Of California |
AMILOID BINDING AGENTS
|
US9522153B2
(en)
|
2009-12-22 |
2016-12-20 |
Allergan, Inc. |
Compositions and methods for lowering intraocular pressure
|
DE102010009475B4
(de)
|
2010-02-26 |
2011-11-24 |
F. Holzer Gmbh |
Verfahren zur Herstellung eines dosierbaren applikationsfertigen Präparates
|
SG10201502484SA
(en)
|
2010-03-30 |
2015-05-28 |
Verseon Corp |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
CA2796041A1
(en)
|
2010-04-07 |
2011-10-13 |
Allergan, Inc. |
Combinations of preservative compositions for ophthalmic formulations
|
EP2555748A2
(de)
|
2010-04-07 |
2013-02-13 |
Allergan, Inc. |
Konservierungsstoffkombinationen für ophthalmische zusammensetzungen
|
JP5713791B2
(ja)
*
|
2010-05-12 |
2015-05-07 |
テイカ製薬株式会社 |
眼科用剤
|
JP5870459B2
(ja)
|
2010-08-27 |
2016-03-01 |
わかもと製薬株式会社 |
点眼用水性組成物
|
US8530449B2
(en)
|
2010-09-09 |
2013-09-10 |
Assad S. Sawaya |
Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
|
CN103209684A
(zh)
|
2010-09-13 |
2013-07-17 |
贝夫-厄克斯股份有限公司 |
包含异味掩蔽剂的含水药物递送系统
|
WO2012058645A1
(en)
|
2010-10-29 |
2012-05-03 |
Biogen Idec Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
WO2012112451A1
(en)
|
2011-02-14 |
2012-08-23 |
Allergan, Inc. |
Ester derivatives of bimatoprost compositions and methods
|
DK2710007T3
(da)
|
2011-05-17 |
2020-01-27 |
Principia Biopharma Inc |
Kinasehæmmere
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
PL2710005T3
(pl)
|
2011-05-17 |
2017-07-31 |
Principia Biopharma Inc. |
Inhibitory kinazy tyrozynowej
|
JP2014521594A
(ja)
|
2011-05-25 |
2014-08-28 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
長持続期間デュアルホルモンコンジュゲート
|
WO2013006569A2
(en)
|
2011-07-01 |
2013-01-10 |
The Regents Of The University Of California |
Herpes virus vaccine and methods of use
|
JP6342805B2
(ja)
|
2011-09-02 |
2018-06-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
置換ピラゾロ[3,4−d]ピリミジンおよびその用途
|
CA2853729A1
(en)
|
2011-10-28 |
2013-05-02 |
Board Of Regents, The University Of Texas System |
Novel compositions and methods for treating cancer
|
EP2836482B1
(de)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur behandlung von krebs
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
EP2858500A4
(de)
|
2012-06-08 |
2016-04-06 |
Biogen Ma Inc |
Hemmer der bruton-tyrosinkinase
|
WO2013188452A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
CA2882743C
(en)
|
2012-08-27 |
2021-11-30 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
ES2731833T3
(es)
|
2012-09-10 |
2019-11-19 |
Principia Biopharma Inc |
Compuestos pirazolopirimidínicos comos inhibidores de cinasas
|
BR112015006828A8
(pt)
|
2012-09-26 |
2019-09-17 |
Univ California |
composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
|
WO2014066435A1
(en)
|
2012-10-22 |
2014-05-01 |
City Of Hope |
Etp derivatives
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
EP2953950B1
(de)
|
2013-02-11 |
2021-01-13 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen
|
EP2968296B1
(de)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gammasekretasemodulatoren
|
WO2014143592A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid ip receptors
|
US9295665B2
(en)
|
2013-03-12 |
2016-03-29 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors
|
EP2968215B1
(de)
|
2013-03-14 |
2021-05-05 |
The Regents of the University of California |
Thiosaccharid-mukolytika
|
AU2014236370C1
(en)
|
2013-03-14 |
2019-01-17 |
City Of Hope |
5-bromo-indirubins
|
EP2968270A4
(de)
|
2013-03-14 |
2016-08-17 |
Univ California |
Modulation von k2p-kanälen
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
MX2015012867A
(es)
|
2013-03-15 |
2016-06-10 |
Verseon Corp |
Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
|
DK3460054T3
(da)
|
2013-03-15 |
2021-01-18 |
Atyr Pharma Inc |
Histidyl-tRNA-syntetase-Fc-konjugater
|
AU2014233520B2
(en)
|
2013-03-15 |
2019-02-21 |
The Regents Of The University Of California |
Modulators of the eIF2alpha pathway
|
AU2014238478B2
(en)
|
2013-03-15 |
2018-07-19 |
Verseon Corporation |
Halogenopyrazoles as inhibitors of thrombin
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
WO2014143643A1
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California, A California Corporation |
Acyclic nucleoside phosphonate diesters
|
CN105338985A
(zh)
|
2013-03-15 |
2016-02-17 |
阿勒根公司 |
用于增加瘦素生成的比马前列素
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2014190207A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
CA2917527C
(en)
|
2013-07-15 |
2022-06-14 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
LT3035926T
(lt)
|
2013-08-19 |
2020-11-25 |
The Regents Of The University Of California |
Junginiai ir būdai, skirti epileptinio sutrikimo gydymui
|
JP2016530273A
(ja)
|
2013-08-20 |
2016-09-29 |
シティ・オブ・ホープCity of Hope |
癌を治療するためのhdac8阻害剤
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
MX370103B
(es)
|
2013-12-11 |
2019-12-02 |
Biogen Ma Inc |
Compuestos de biarilo utiles para el tratamiento de enfermedades humanas en oncologia, neurologia e inmunologia.
|
EP3444251B1
(de)
|
2013-12-11 |
2023-06-07 |
Biogen MA Inc. |
Zur behandlung von erkrankungen des menschen in der onkologie, neurologie und immunologie geeignete biarylverbindungen
|
TWI673279B
(zh)
|
2013-12-23 |
2019-10-01 |
美國紀念斯隆-凱特琳癌症中心 |
用於放射性標記之方法及試劑
|
EP3091985A4
(de)
|
2014-01-10 |
2017-11-29 |
Manistee Partners LLC |
Behandlung von migränen
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
HRP20220759T1
(hr)
|
2014-02-11 |
2022-09-02 |
Mitokinin, Inc. |
Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
|
CA2937752C
(en)
|
2014-02-14 |
2023-02-07 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
CN106029643A
(zh)
|
2014-02-20 |
2016-10-12 |
阿勒根公司 |
通过使用β-氯环戊烷的亲水性酯前药减少中心角膜增厚
|
SG11201606858RA
(en)
|
2014-02-21 |
2016-09-29 |
Principia Biopharma Inc |
Salts and solid form of a btk inhibitor
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
EP3128842B1
(de)
|
2014-03-26 |
2023-07-26 |
City of Hope |
Behandlung von brca1-defektem krebs oder -resistentem krebs
|
WO2015157313A1
(en)
|
2014-04-07 |
2015-10-15 |
The Regents Of The University Of California |
Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
|
CA2948621A1
(en)
|
2014-05-13 |
2015-11-19 |
Memorial Sloan Kettering Cancer Center |
Hsp70 modulators and methods for making and using the same
|
US10166246B2
(en)
|
2014-05-27 |
2019-01-01 |
City Of Hope |
TGR5 agonist complexes for treating diabetes and cancer
|
US9012402B1
(en)
|
2014-06-11 |
2015-04-21 |
James Blanchard |
Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
|
US10414814B2
(en)
|
2014-07-03 |
2019-09-17 |
City Of Hope |
Tumor-selective CTLA-4 antagonists
|
US11072681B2
(en)
|
2014-07-28 |
2021-07-27 |
The Regents Of The University Of California |
Compositions and methods of making polymerizing nucleic acids
|
US10980744B2
(en)
|
2014-08-08 |
2021-04-20 |
The Regents Of The University Of California |
High density peptide polymers
|
CN113620978A
(zh)
|
2014-09-11 |
2021-11-09 |
加利福尼亚大学董事会 |
mTORC1抑制剂
|
KR102589658B1
(ko)
|
2014-09-15 |
2023-10-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
뉴클레오타이드 유사체
|
CA2960790A1
(en)
|
2014-09-17 |
2016-03-24 |
Verseon Corporation |
Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
AU2015327817B2
(en)
|
2014-10-02 |
2020-04-23 |
Allergan, Inc. |
Ester prodrugs of gamma-lactams and their use
|
WO2016061145A1
(en)
|
2014-10-13 |
2016-04-21 |
Symic Biomedical, Inc. |
Synthetic proteoglycans for preventing tissue adhesion
|
WO2016061147A1
(en)
|
2014-10-13 |
2016-04-21 |
John Eric Paderi |
Luminal vessel coating for arteriovenous fistula
|
WO2016065083A1
(en)
|
2014-10-21 |
2016-04-28 |
Symic Biomedical, Inc. |
Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
|
MA41197B1
(fr)
|
2014-12-18 |
2021-01-29 |
Principia Biopharma Inc |
Traitement de le pemphigus
|
EP3244907B1
(de)
|
2015-01-13 |
2020-02-19 |
City of Hope |
Peptid-linkermasken mit ctla4-bindenden proteinen
|
MX2017009272A
(es)
|
2015-01-16 |
2018-04-11 |
|
Anticuerpos que penetran en células.
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138138A1
(en)
|
2015-02-25 |
2016-09-01 |
The Regents Of The University Of California |
5ht agonists for treating disorders
|
JP2018510138A
(ja)
|
2015-02-27 |
2018-04-12 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
US11072592B2
(en)
|
2015-02-27 |
2021-07-27 |
The Regents Of The University Of California |
Small molecules that enable cartilage rejuvenation
|
CN107405333A
(zh)
|
2015-02-27 |
2017-11-28 |
维颂公司 |
作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
|
US20160256410A1
(en)
|
2015-03-02 |
2016-09-08 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy in mammals with cannabinoids
|
US10383816B2
(en)
|
2015-03-02 |
2019-08-20 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with cannabinoid combination products
|
WO2016161018A1
(en)
|
2015-03-30 |
2016-10-06 |
City Of Hope |
Mechanically interlocking complexes
|
TW201702232A
(zh)
|
2015-04-10 |
2017-01-16 |
亞瑞克西斯製藥公司 |
經取代之喹唑啉化合物及其使用方法
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
EP3283482B1
(de)
|
2015-04-17 |
2022-04-06 |
Ludwig Institute for Cancer Research Ltd |
Plk4 hemmer
|
WO2016172726A1
(en)
|
2015-04-24 |
2016-10-27 |
The Regents Of The University Of California |
Modulators of ror1-ror2 binding
|
AU2016265845B2
(en)
|
2015-05-15 |
2020-10-08 |
City Of Hope |
Chimeric antigen receptor compositions
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
WO2016201169A1
(en)
|
2015-06-10 |
2016-12-15 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
MA42510A
(fr)
|
2015-06-10 |
2018-06-06 |
Biogen Ma Inc |
Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
|
US20180305350A1
(en)
|
2015-06-24 |
2018-10-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
CN114224907A
(zh)
|
2015-07-02 |
2022-03-25 |
希望之城 |
包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
JP7104462B2
(ja)
|
2015-08-06 |
2022-07-21 |
シティ・オブ・ホープ |
細胞透過性タンパク質-抗体コンジュゲートおよび使用方法
|
EP3128007A1
(de)
|
2015-08-07 |
2017-02-08 |
Gene Signal International SA |
Sterile emulsion mit einem stabilen phosphorothioat-oligonukleotid
|
WO2017040693A1
(en)
|
2015-08-31 |
2017-03-09 |
The Regents Of The University Of California |
Broad spectrum antiviral compounds and uses thereof
|
EP3350181B1
(de)
|
2015-09-02 |
2023-11-01 |
The Regents of The University of California |
Her3-liganden und ihre verwendungen
|
EP3350167A4
(de)
|
2015-09-04 |
2019-04-03 |
City of Hope |
Androgen-rezeptor-antagonisten
|
US11253521B2
(en)
|
2015-09-25 |
2022-02-22 |
Ludwig Institute For Cancer Research Ltd |
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
|
EP3356339A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017066349A1
(en)
|
2015-10-13 |
2017-04-20 |
Symic Ip, Llc |
Ve-cadherin binding bioconjugate
|
US10801026B2
(en)
|
2015-10-15 |
2020-10-13 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
CA3002924A1
(en)
|
2015-10-23 |
2017-04-27 |
Erx Pharmaceuticals Inc. |
Analogs of celastrol
|
AU2016342352B2
(en)
|
2015-10-23 |
2022-06-02 |
Sunesis Pharmaceuticals, Inc. |
Heterocyclic PDK1 inhibitors for use to treat cancer
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
JP7015059B2
(ja)
|
2015-11-16 |
2022-02-15 |
アラクセス ファーマ エルエルシー |
置換複素環式基を含む2-置換キナゾリン化合物およびその使用方法
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
CN108603037B
(zh)
|
2015-12-10 |
2020-11-17 |
希望之城 |
细胞穿透花青偶联抗体
|
RU2730855C2
(ru)
|
2015-12-24 |
2020-08-26 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа |
Кфтр регуляторы и способы их применения
|
PT3394040T
(pt)
|
2015-12-24 |
2022-03-24 |
Univ California |
Reguladores de cftr e seus métodos de uso
|
AU2017205389B2
(en)
|
2016-01-05 |
2021-05-20 |
The Regents Of The University Of California |
Benzothiazole amphiphiles
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
US11208411B2
(en)
|
2016-03-17 |
2021-12-28 |
The Regents Of The University Of California |
Compositions and methods for treating parasitic diseases
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
GR1009006B
(el)
|
2016-04-01 |
2017-04-04 |
Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων |
Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χρηση περιεχον βιματοπροστη και τιμολολη
|
GR1009040B
(el)
|
2016-04-19 |
2017-05-19 |
Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων |
Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
|
US20170312273A1
(en)
|
2016-04-25 |
2017-11-02 |
Forma Therapeutics, Inc. |
Methods of using fasn inhibitors
|
AU2017257151A1
(en)
|
2016-04-29 |
2018-11-15 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
TWI763668B
(zh)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
CN109153688A
(zh)
|
2016-05-12 |
2019-01-04 |
安纳考尔医药公司 |
氧杂硼杂环戊烷酯类及其用途
|
WO2017205611A1
(en)
|
2016-05-26 |
2017-11-30 |
The Regents Of The University Of California |
Estrogen receptor modulator combinations
|
IL263815B
(en)
|
2016-06-29 |
2022-07-01 |
Principia Biopharma Inc |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
|
US11045493B2
(en)
|
2016-07-11 |
2021-06-29 |
The Regents Of The University Of California |
Synthetic melanin nanoparticles and uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
CA3031443A1
(en)
|
2016-07-21 |
2018-01-25 |
Biogen Ma Inc. |
Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors
|
US10179787B2
(en)
|
2016-07-29 |
2019-01-15 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
US20180049994A1
(en)
|
2016-08-16 |
2018-02-22 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with caryophyllene
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
US11780895B2
(en)
|
2016-09-13 |
2023-10-10 |
The Jackson Laboratory |
Targeted DNA demethylation and methylation
|
JP7088912B2
(ja)
|
2016-09-15 |
2022-06-21 |
シティ・オブ・ホープ |
ジチオetp誘導体
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
EP3519402A1
(de)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
BR112019012263A2
(pt)
|
2016-12-15 |
2020-01-28 |
Univ California |
composições e métodos para tratar câncer
|
EP3573964A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophen- und benzothiazolverbindungen und verfahren zur verwendung davon
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
US11059819B2
(en)
|
2017-01-26 |
2021-07-13 |
Janssen Biotech, Inc. |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
US10052343B1
(en)
|
2017-02-03 |
2018-08-21 |
Gene Signal International Sa |
Sterile formulation comprising a stable phosphorothioate oligonucleotide
|
CN110520134B
(zh)
|
2017-02-03 |
2023-07-18 |
基因信号国际公司 |
包含稳定的硫代磷酸酯寡核苷酸的无菌制剂
|
WO2018218071A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
CA3063440A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
KR20200019228A
(ko)
|
2017-06-21 |
2020-02-21 |
미토키닌, 인크. |
신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법
|
WO2019006371A1
(en)
|
2017-06-30 |
2019-01-03 |
City Of Hope |
COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
|
US10821075B1
(en)
|
2017-07-12 |
2020-11-03 |
James Blanchard |
Compositions for topical application of a medicaments onto a mammalian body surface
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
MA50664A
(fr)
|
2017-09-29 |
2020-08-05 |
Genentech Inc |
Complexes d'antibiotiques peptidiques et leurs méthodes d'utilisation
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
CA3078942A1
(en)
|
2017-10-10 |
2019-04-18 |
Syros Pharmaceuticals, Inc. |
Pyrrolotriazine compounds and methods of inhibiting tam kinases
|
US11618780B2
(en)
|
2017-10-20 |
2023-04-04 |
City Of Hope |
Composition and method for activating latent human immunodeficiency virus (HIV)
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
CA3080971A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
WO2019090074A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
EP3704091A1
(de)
|
2017-11-02 |
2020-09-09 |
Calico Life Sciences LLC |
Modulatoren eines integrierten spannungswegs
|
CA3080948A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
BR112020008825A2
(pt)
|
2017-11-02 |
2020-10-20 |
Calico Life Sciences Llc |
moduladores da via de estresse integrada
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
US20200361881A1
(en)
|
2017-11-02 |
2020-11-19 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
BR112020009055A2
(pt)
|
2017-11-06 |
2020-11-03 |
Rapt Therapeutics, Inc. |
moduladores de receptor de quimiocina para tratamento de câncer positivo para vírus epstein barr
|
KR20200096941A
(ko)
|
2017-12-07 |
2020-08-14 |
앰플릭스 파마슈티컬스, 인크. |
헤테로사이클 치환된 피리딘 유도체 항진균제
|
WO2019126037A1
(en)
|
2017-12-19 |
2019-06-27 |
City Of Hope |
Modified tracrrnas grnas, and uses thereof
|
WO2019143719A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
EP3740206B1
(de)
|
2018-01-16 |
2024-03-06 |
Syros Pharmaceuticals, Inc. |
Hemmer der cyclinabhängigen kinase 7 (cdk7)
|
KR20200125932A
(ko)
|
2018-01-26 |
2020-11-05 |
랩트 테라퓨틱스, 인크. |
케모카인 수용체 조정제 및 그의 용도
|
CA3093802A1
(en)
|
2018-03-13 |
2019-09-19 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
CA3098562A1
(en)
|
2018-04-27 |
2019-10-31 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
US20190336609A1
(en)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
|
AU2019262979B2
(en)
|
2018-05-01 |
2023-07-06 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mTOR inhibitors
|
EP3787618A4
(de)
|
2018-05-04 |
2022-05-04 |
Cirius Therapeutics, Inc. |
Thiazolidindionanaloga zur behandlung von nafld und stoffwechselerkrankungen
|
EP3802544A1
(de)
|
2018-06-05 |
2021-04-14 |
RAPT Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkylverbindungen und deren therapeutische verwendungen
|
WO2019246513A1
(en)
|
2018-06-21 |
2019-12-26 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
JP2021530445A
(ja)
|
2018-06-25 |
2021-11-11 |
アンプリックス ファーマシューティカルズ,インク. |
複素環およびアミノ基によって置換されたピリジン誘導体
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
TWI771621B
(zh)
|
2018-10-11 |
2022-07-21 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
WO2020088659A1
(en)
|
2018-11-01 |
2020-05-07 |
Lynk Pharmaceuticals Co. Ltd. |
Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
|
CN113242734A
(zh)
*
|
2018-11-26 |
2021-08-10 |
艾葳生物科技有限公司 |
用于药物递送的药用生物可溶凝胶
|
KR20230074822A
(ko)
|
2019-03-14 |
2023-05-31 |
칼리코 라이프 사이언시스 엘엘씨 |
단백질 티로신 포스파타제 억제제 및 이의 사용 방법
|
CA3138182A1
(en)
|
2019-04-30 |
2020-11-05 |
Calico Life Sciences Llc |
Substituted cycloalkyls as modulators of the integrated stress pathway
|
FR3095592B1
(fr)
*
|
2019-05-02 |
2021-05-21 |
Unither Pharmaceuticals |
Composition à base de gomme gellane et de phényléphrine, procédé de fabrication et utilisation comme produit ophtalmique
|
CN114126596A
(zh)
|
2019-05-15 |
2022-03-01 |
贝克森生物医药公司 |
用于皮下注射的氯胺酮制剂
|
MX2022003192A
(es)
|
2019-09-18 |
2022-04-11 |
Novartis Ag |
Proteinas de fusion nkg2d y sus usos.
|
EP4031547A1
(de)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Plasma-kallikreininhibitoren und verwendungen dafür
|
EP4031245A1
(de)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Heteroaryl-plasma-kallikrein-inhibitoren
|
KR20220101099A
(ko)
|
2019-11-13 |
2022-07-19 |
랩트 테라퓨틱스, 인크. |
C-c 케모카인 수용체 유형 4 길항제의 결정 형태 및 이의 용도
|
JP2023507774A
(ja)
|
2019-12-18 |
2023-02-27 |
カリコ ライフ サイエンシーズ エルエルシー |
タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
|
EP4126076A1
(de)
|
2020-03-31 |
2023-02-08 |
Sentiss Pharma Private Limited |
Sterilisationsverfahren von timololgelbildender lösung durch aseptische filtration
|
GR1010024B
(el)
|
2020-05-06 |
2021-06-01 |
Φαρματεν Α.Β.Ε.Ε. |
Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
|
AU2021276656A1
(en)
|
2020-05-19 |
2022-11-24 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
KR20230051486A
(ko)
|
2020-08-18 |
2023-04-18 |
사이빈 아이알엘 리미티드 |
치료 펜에틸아민 조성물 및 사용 방법
|
US20220133735A1
(en)
|
2020-11-02 |
2022-05-05 |
Trethera Corporation |
Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof
|
JP2023551145A
(ja)
|
2020-11-18 |
2023-12-07 |
ベクソン バイオメディカル,インク. |
医薬化合物の錯化剤塩製剤
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
WO2022197763A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Inhibitors of plasma kallikrein
|
EP4308227A1
(de)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Imidazopyridinylhemmer von plasmakallikrein
|
EP4308228A1
(de)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Plasmakallikreinhemmer
|
JP2024516073A
(ja)
|
2021-03-17 |
2024-04-12 |
武田薬品工業株式会社 |
血漿カリクレインのヘテロアリール阻害剤
|
EP4308564A1
(de)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Polycyclische inhibitoren von plasmakallikrein
|
WO2023156453A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
WO2023156450A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
WO2023196432A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|